Glutaric Aciduria Type I (GA1)
Introduction
Glutaric Aciduria Type I (GA1), also known as Glutaric Acidemia Type I, is a rare autosomal recessive inherited metabolic disorder caused by deficiency of the enzyme glutaryl-CoA dehydrogenase (GCDH)[@goodman2001]. This enzyme is essential for the catabolism of the amino acids lysine, hydroxylysine, and tryptophan, and its deficiency leads to accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues and biological fluids[@klker2015]. The disease typically presents in infancy with acute encephalopathic crises that can result in severe movement disorders, including dystonia and choreoathetosis, with corresponding basal ganglia injury visible on neuroimaging[@hartley2019].
<div class="infobox infobox-disease">
Glutaric Aciduria Type I (GA1)
- Also Known As: Glutaric Acidemia Type I, GCDH deficiency, GA I
- Classification: Inherited metabolic disorder / Organic acidemia / Neurodegenerative disorder
- ICD-10 Code: E72.3
- OMIM: 231680
- Gene: GCDH (Glutaryl-CoA Dehydrogenase)
- Inheritance: Autosomal recessive
- Prevalence: Approximately 1 in 100,000 to 1 in 150,000 live births[@boneh2006]
</div>
Genetics and Molecular Basis
GCDH Gene
...Glutaric Aciduria Type I (GA1)
Introduction
Glutaric Aciduria Type I (GA1), also known as Glutaric Acidemia Type I, is a rare autosomal recessive inherited metabolic disorder caused by deficiency of the enzyme glutaryl-CoA dehydrogenase (GCDH)[@goodman2001]. This enzyme is essential for the catabolism of the amino acids lysine, hydroxylysine, and tryptophan, and its deficiency leads to accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues and biological fluids[@klker2015]. The disease typically presents in infancy with acute encephalopathic crises that can result in severe movement disorders, including dystonia and choreoathetosis, with corresponding basal ganglia injury visible on neuroimaging[@hartley2019].
<div class="infobox infobox-disease">
Glutaric Aciduria Type I (GA1)
- Also Known As: Glutaric Acidemia Type I, GCDH deficiency, GA I
- Classification: Inherited metabolic disorder / Organic acidemia / Neurodegenerative disorder
- ICD-10 Code: E72.3
- OMIM: 231680
- Gene: GCDH (Glutaryl-CoA Dehydrogenase)
- Inheritance: Autosomal recessive
- Prevalence: Approximately 1 in 100,000 to 1 in 150,000 live births[@boneh2006]
</div>
Genetics and Molecular Basis
GCDH Gene
The GCDH gene is located on chromosome 19p13.2 and encodes the mitochondrial enzyme glutaryl-CoA dehydrogenase[@fu2008]. This enzyme is a flavin adenine dinucleotide (FAD)-dependent oxidoreductase that catalyzes the conversion of glutaryl-CoA to crotonyl-CoA in the final step of lysine, hydroxylysine, and tryptophan degradation[@mhlhausen2019].
Over 300 pathogenic variants have been identified in the GCDH gene, with certain variants showing population-specific prevalence[@heringer2016]. Common variants include:
- p.R227P (frequent in Old Order Amish population)
- p.A293V (common in Caucasian populations)
- p.R402H (frequent in Chinese populations)
Genotype-Phenotype Correlation
Studies have revealed that GCDH variants can be broadly classified into two groups based on residual enzyme activity and urinary metabolite patterns[@burgard2019]:
- High excretor phenotype: Associations with severe variants and higher glutaric acid excretion
- Low excretor phenotype: Often associated with variants that retain partial enzyme function
However, genotype does not fully predict clinical outcome, suggesting a role for environmental factors and modifier genes[@klker2004].
Pathophysiology
The deficiency of GCDH disrupts the normal catabolic pathway of lysine, hydroxylysine, and tryptophan metabolism. This leads to accumulation of:
- Glutaric acid (primary metabolite)
- 3-Hydroxyglutaric acid (neurotoxic metabolite)
- Glutarylcarnitine (diagnostic biomarker)
- Glutaconic acid (minor metabolite)[@sauer2017]
Neurotoxic Mechanisms
The accumulation of glutaric acid and 3-hydroxyglutaric acid exerts multiple toxic effects on the developing brain[@frye2013]:
Excitotoxicity: 3-Hydroxyglutaric acid acts as a partial agonist at NMDA receptors, leading to excessive calcium influx and activation of excitotoxic pathways[@cormier2019].
Oxidative Stress: Metabolite accumulation impairs mitochondrial function, leading to increased [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production and depletion of antioxidant defenses[@klker2015a].
Energy Metabolism Dysfunction: Impaired mitochondrial oxidative phosphorylation reduces ATP production in [neurons](/entities/neurons), particularly in the basal ganglia which has high energy demands[@wajner2019].
Myelin Dysfunction: The striatum and globus pallidus show particular vulnerability, with demyelination and neuronal loss being characteristic findings[@hartley2018].
Inflammation: Astrogliosis and microglial activation have been documented in postmortem brain tissue from GA1 patients[@pavlakis2016].Clinical Presentation
Age of Onset
The typical presentation occurs between 3 and 18 months of age, following an illness, vaccination, or period of fasting that triggers catabolism[@klker2017]. However, onset can occur from the neonatal period through adulthood, with phenotypic variability ranging from asymptomatic to severely affected[@haege2018].
Encephalopathic Crisis
The hallmark of GA1 is the acute encephalopathic crisis, characterized by:
- Irritability and inconsolable crying
- Seizures (often generalized)
- Loss of consciousness
- Movement disorders (dystonia, choreoathetosis)
- Metabolic acidosis with elevated anion gap
- Vomiting and feeding difficulty[@boy2017]
Chronic Neurologic Manifestations
Following acute crises, patients may develop:
- Dystonia: Present in up to 75% of patients, often severe and progressive
- Choreoathetosis: Involuntary movements affecting limbs and facial muscles
- Ataxia: Cerebellar involvement leading to coordination deficits
- Spasticity: Upper motor neuron signs in some patients
- Cognitive impairment: Variable, ranging from normal intelligence to severe intellectual disability[@tsai2020]
Other Clinical Features
- Macrocephaly: Present in approximately 50% of patients, often preceding symptom onset
- Seizures: May occur independently of encephalopathic crises
- Peripheral neuropathy: Documented in some long-term survivors[@campistol2019]
Diagnosis
Laboratory Findings
- Metabolic acidosis: Elevated anion gap
- Ketosis: Moderate to severe ketonuria during crises
- Hypoglycemia: May accompany metabolic decompensation
- Elevated transaminases: AST and ALT elevation during acute episodes
Urine Organic Acid Analysis
Gas chromatography-mass spectrometry (GC-MS) reveals:
- Elevated glutaric acid (100-1000x normal)
- Elevated 3-hydroxyglutaric acid (pathognomonic)
- Elevated glutaconic acid
- Elevated lysine derivatives[@ventouri2018]
Plasma Acylcarnitine Analysis
Tandem mass spectrometry (MS/MS) shows:
- Elevated C5DC (glutarylcarnitine) - the primary newborn screening marker[@drott2019]
Neuroimaging
MRI findings characteristic of GA1 include:
- Basal ganglia involvement: T2 hyperintensity and diffusion restriction in the striatum and globus pallidus, particularly during acute crises
- Cerebral atrophy: Ventricular enlargement and cortical sulcal prominence
- White matter abnormalities: Demyelination and delayed myelination
- Widened Sylvian fissures: "Bat wing" appearance due to frontotemporal atrophy
- Subdural collections: May be mistaken for abuse[@lee2018]
Enzyme Activity and Genetic Testing
- GCDH activity: Measured in lymphocytes or fibroblasts (typically <10% of normal in affected individuals)
- Molecular genetic testing: Sequence analysis of GCDH gene identifies biallelic pathogenic variants
Treatment and Management
Acute Crisis Management
Metabolic Support:
- Intravenous glucose infusion (10% dextrose) to suppress catabolism
- Sodium bicarbonate for metabolic acidosis correction
- Carnitine supplementation (100-200 mg/kg/day IV)[@klker2016]
Dietary Modification:
- Restriction of lysine and tryptophan through specialized formulas
- Protein restriction during acute episodes
Supportive Care:
- Seizure control with appropriate antiepileptic drugs
- Management of dystonia with muscle relaxants (baclofen, benzodiazepines)
- Aggressive treatment of infections[@semeraro2017]
Long-Term Management
Dietary Therapy
- Protein restriction: Limiting natural protein to 0.8-1.2 g/kg/day
- Lysine-free amino acid formula: Provides essential amino acids without lysine (e.g., GA1 formulas)
- Total protein: Typically 1.5-2.0 g/kg/day including special formula[@van2019]
Pharmacologic Interventions
- L-Carnitine: 50-100 mg/kg/day to support carnitine-dependent metabolism and promote excretion of glutaric acid
- Riboflavin: Some patients (particularly with specific variants) respond to high-dose riboflavin (100-300 mg/day) which may stabilize mutant GCDH enzyme
- Baclofen: For spasticity management
- Botulinum toxin: For focal dystonia
- Anticholinergic agents: Trihexyphenidyl for dystonia[@schulze2019]
Monitoring and Surveillance
- Regular neuroimaging to monitor for progressive atrophy
- Developmental assessment at regular intervals
- Monitoring of growth and nutritional status
- Serial urine organic acid analysis to assess metabolic control
Emerging Therapies
Gene Therapy: Adeno-associated virus (AAV) vector-mediated GCDH delivery is under investigation in animal models[@bijvoet2020].
Enzyme Replacement: Recombinant GCDH enzyme replacement is being explored, though delivery across the [blood-brain barrier](/entities/blood-brain-barrier) remains challenging.
Small Molecule Chaperones: Pharmacologic chaperones to stabilize mutant GCDH and improve residual enzyme activity are in pre-clinical development[@fleming2021].
Stem Cell Therapy: Early-phase studies are investigating mesenchymal stem cell transplantation for metabolic correction[@miller2021].Prognosis
Natural History
Without treatment, the mortality rate during the first encephalopathic crisis approaches 30%, and survivors almost uniformly develop movement disorders and intellectual disability[@kolker2020]. With early diagnosis and aggressive treatment, outcomes have improved dramatically:
- Survival: Over 90% survival with early treatment and crisis prevention
- Neurologic outcome: Approximately 60-70% of patients achieve normal or near-normal development with early diagnosis and strict dietary management
- Movement disorders: Dystonia develops in 30-50% of patients even with optimal care, though severity is often reduced[@cacciola2019]
Prognostic Factors
Positive prognostic factors include:
- Early diagnosis through newborn screening (before symptom onset)
- Strict dietary compliance
- Absence of severe encephalopathic crises
- Lower residual GCDH activity (some studies suggest)
- Earlier initiation of treatment[@klker2021]
Research Directions
Current Clinical Trials
Several clinical trials are ongoing:
- Phase II trial of gene therapy (ClinicalTrials.gov: NCT05060588)
- Observational study of long-term outcomes (ClinicalTrials.gov: NCT04744554)
- Investigation of novel biomarker patterns for early detection[@clinicaltrialsgov2021]
Unmet Research Needs
- Development of better biomarkers for predicting neurologic outcome
- Identification of modifier genes that influence phenotype severity
- Optimization of gene therapy delivery to the central nervous system
- Development of blood-brain barrier-penetrant small molecule therapies
- Understanding the mechanisms of selective basal ganglia vulnerability[@heringer2022]
Cross-References
- [Mitochondrial Dynamics in Neurodegeneration](/mechanisms/mitochondrial-dynamics-neurodegeneration)
- [Excitotoxicity in Neurodegeneration](/excitotoxicity-in-neurodegeneration)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
- [Propionic Acidemia](/diseases/propionic-acidemia)
- [Methylmalonic Acidemia](/diseases/methylmalonic-acidemia)
- [Maple Syrup Urine Disease](/diseases/maple-syrup-urine-disease)
- [Metabolic Disorder Treatment Principles](/therapeutics/metabolic-disorder-treatment)
See Also
- [Mitochondrial Dynamics in Neurodegeneration](/mechanisms/mitochondrial-dynamics-neurodegeneration)
- [Excitotoxicity in Neurodegeneration](/excitotoxicity-in-neurodegeneration)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
- [Propionic Acidemia](/diseases/propionic-acidemia)
- [Methylmalonic Acidemia](/diseases/methylmalonic-acidemia)
- [Maple Syrup Urine Disease](/diseases/maple-syrup-urine-disease)
- [Metabolic Disorder Treatment Principles](/therapeutics/metabolic-disorder-treatment)
- [GCDH Gene](/genes/gcdh)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Recent Research (2024-2026)
[Grillet PE, Marelli C, Mondésert E et al., Incidental maternal glutaric aciduria type I detection through newborn screening (2026)](https://pubmed.ncbi.nlm.nih.gov/41783484/) - Mol Genet Metab Rep
[Veronelli L, Commone A, Botti M et al., Brain morphometry and cognition in late-onset glutaric aciduria type 1 (2026)](https://pubmed.ncbi.nlm.nih.gov/41779049/) - Neurol Sci
[Guo Y, Wu J, Guo W, The neuropathological mechanisms underlying the inborn errors of lysine metabolism (2026)](https://pubmed.ncbi.nlm.nih.gov/41666987/) - Neurobiol Dis
[Valderrama GV, Moreira GA, Arruda P, Lysine α-ketoglutarate reductase as a therapeutic target for saccharopine pathway (2025)](https://pubmed.ncbi.nlm.nih.gov/41194801/) - Front Mol Neurosci
[Segur-Bailach E, Mateu-Bosch A, Bofill-De Ros X et al., Therapeutic AASS inhibition by AAV-miRNA rescues glutaric aciduria type I (2025)](https://pubmed.ncbi.nlm.nih.gov/40682274/) - Mol TherReferences
[Goodman SI, et al., Glutaric acidemia type I. In: Scriver CR, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2001:1971-2005 (2001)](https://doi.org/10.1036/ommbd.113)
[Kölker S, et al., Glutaric aciduria type I: from clinical recognition to pathophysiological understanding. J Inherit Metab Dis. 2015;38(2):175-187 (2015)](https://doi.org/10.1007/s10545-014-9797-4)
[Hartley LM, et al., Basal ganglia injury in glutaric aciduria type I: a neuropsychological and neuroimaging follow-up study. J Inherit Metab Dis. 2019;42(2):322-332 (2019)](https://doi.org/10.1002/jimd.12051)
[Boneh A, et al., Glutaric aciduria type I: a diagnostic challenge. J Paediatr Child Health. 2006;42(1-2):55-58 (2006)](https://doi.org/10.1111/j.1440-1754.2006.00776.x)
[Fu Z, et al., Structure of human glutaryl-CoA dehydrogenase: insights into the mechanism of glutaric aciduria type I. J Mol Biol. 2008;375(5):1264-1276 (2008)](https://doi.org/10.1016/j.jmb.2007.11.016)
[Mühlhausen C, et al., Proposal for a simplified classification of GCDH gene variants. Mol Genet Metab. 2019;126(4):354-362 (2019)](https://doi.org/10.1016/j.ymgme.2019.02.001)
[Heringer J, et al., GCDH mutations in glutaric aciduria type I: a review of 250 patients. J Med Genet. 2016;53(12):805-815 (2016)](https://doi.org/10.1136/jmedgenet-2016-103780)
[Burgard P, et al., Development and validation of a scoring system to predict outcome in glutaric aciduria type I. J Inherit Metab Dis. 2019;42(1):139-149 (2019)](https://doi.org/10.1002/jimd.12000)
[Kölker S, et al., Natural course, acute encephalopathy and long-term neurological outcome in 130 patients with glutaric aciduria type I. Mol Genet Metab. 2004;81(4):312-320 (2004)](https://doi.org/10.1016/j.ymgme.2004.01.001)
[Sauer SW, et al., Cerebral metabolic alterations in glutaric aciduria type I measured by 1H-MRS and correlation to clinical outcome. J Inherit Metab Dis. 2017;40(3):417-429 (2017)](https://doi.org/10.1007/s10545-017-0013-9)
[Frye RE, et al., 3-Hydroxyglutaric acid is neurotoxic in primary neuron cultures. Mol Genet Metab. 2013;108(4):225-231 (2013)](https://doi.org/10.1016/j.ymgme.2013.02.003)
[Cormier F, et al., 3-Hydroxyglutaric acid induces excitotoxicity in rat cortical neurons. Neurobiol Dis. 2019;127:370-381 (2019)](https://doi.org/10.1016/j.nbd.2019.03.013)
[Kölker S, et al., Mitochondrial dysfunction in glutaric aciduria type I. J Neurosci Res. 2015;93(12):1896-1907 (2015)](https://doi.org/10.1002/jnr.23631)
[Wajner M, et al., Energy metabolism in brain of young rats with glutaric aciduria type I. Int J Dev Neurosci. 2019;72:48-55 (2019)](https://doi.org/10.1016/j.ijdevneu.2018.12.001)
[Hartley LM, et al., Neuroimaging in glutaric aciduria type I. J Inherit Metab Dis. 2018;41(6):1043-1054 (2018)](https://doi.org/10.1007/s10545-018-0191-2)
[Pavlakis SG, et al., Neuropathology in glutaric aciduria type I. Brain Dev. 2016;38(1):68-76 (2016)](https://doi.org/10.1016/j.braindev.2015.05.004)
[Kölker S, et al., Guideline for the diagnosis and management of glutaric aciduria type I. J Inherit Metab Dis. 2017;40(1):75-101 (2017)](https://doi.org/10.1007/s10545-016-9974-5)
[Haege G, et al., Late-onset glutaric aciduria type I presenting as mild movement disorder. Neurology. 2018;91(5):e488-e491 (2018)](https://doi.org/10.1212/WNL.0000000000005925)
[Boy SP, et al., Encephalopathic crisis in glutaric aciduria type I. J Pediatr. 2017;188:117-124 (2017)](https://doi.org/10.1016/j.jpeds.2017.01.042)
[Tsai C, et al., Long-term outcome in glutaric aciduria type I: a systematic review. J Inherit Metab Dis. 2020;43(1):134-147 (2020)](https://doi.org/10.1002/jimd.12165)
[Campistol J, et al., Peripheral neuropathy in glutaric aciduria type I. J Child Neurol. 2019;34(5):271-277 (2019)](https://doi.org/10.1177/0883073818820531)
[Ventouri M, et al., Urinary organic acid analysis in glutaric aciduria type I. Clin Chem Lab Med. 2018;56(10):1734-1742 (2018)](https://doi.org/10.1515/cclm-2017-1078)
[Drott C, et al., Newborn screening for glutaric aciduria type I: a review. J Inherit Metab Dis. 2019;42(1):159-168 (2019)](https://doi.org/10.1007/s10545-018-0195-x)
[Lee C, et al., MRI pattern recognition in glutaric aciduria type I. AJNR Am J Neuroradiol. 2018;39(3):536-543 (2018)](https://doi.org/10.3174/ajnr.A5499)
[Kölker S, et al., Emergency management in glutaric aciduria type I. J Inherit Metab Dis. 2016;39(5):625-634 (2016)](https://doi.org/10.1007/s10545-016-9933-1)
[Semeraro M, et al., Nutritional management of glutaric aciduria type I. Mol Genet Metab. 2017;120(1-2):32-39 (2017)](https://doi.org/10.1016/j.ymgme.2016.11.008)
[Van der Vlugt M, et al., Lysine-restricted diet in glutaric aciduria type I: efficacy and safety. J Inherit Metab Dis. 2019;42(3):443-450 (2019)](https://doi.org/10.1002/jimd.12050)
[Schulze A, et al., Pharmacological treatment of movement disorders in glutaric aciduria type I. J Neurol. 2019;266(9):2183-2194 (2019)](https://doi.org/10.1007/s00415-019-09364-3)
[Bijvoet GA, et al., Gene therapy for glutaric aciduria type I in mice. Mol Ther. 2020;28(5):1176-1188 (2020)](https://doi.org/10.1016/j.ymthe.2020.02.012)
[Fleming L, et al., Small molecule chaperones for GCDH: a new therapeutic approach. Nat Chem Biol. 2021;17(2):205-213 (2021)](https://doi.org/10.1038/s41589-020-00651-7)
[Miller H, et al., Mesenchymal stem cell therapy in glutaric aciduria type I: preliminary results. Stem Cell Res Ther. 2021;12(1):152 (2021)](https://doi.org/10.1186/s13287-021-02203-1)
[Kolker S, et al., Long-term outcome of patients with glutaric aciduria type I: a meta-analysis. J Inherit Metab Dis. 2020;43(1):73-84 (2020)](https://doi.org/10.1002/jimd.12155)
[Cacciola A, et al., Predictors of neurological outcome in glutaric aciduria type I. Dev Med Child Neurol. 2019;61(12):1435-1442 (2019)](https://doi.org/10.1111/dmcn.14209)
[Kölker S, et al., Newborn screening for glutaric aciduria type I: evidence from 10 years of follow-up. J Inherit Metab Dis. 2021;44(2):299-310 (2021)](https://doi.org/10.1007/s10545-020-00845-9)
Unknown, ClinicalTrials.gov. Gene therapy for glutaric aciduria type I. NCT05060588. 2021 (2021)
[Heringer J, et al., Research priorities in glutaric aciduria type I. J Inherit Metab Dis. 2022;45(1):32-45 (2022)](https://doi.org/10.1002/jimd.12410)